PERFORMANCE OF EXTENDED PANCREATIC RESECTION IN TREATMENT OF PATIENTS, SUFFERING ITS TUMOUS
Abstract
Objective. To estimate the results of performance of extended pancreatic resection in treatment of patients, suffering pancreatic tumors.
Маterials and methods. In 2010 – 2016 yrs 545 patients were operated for pancreatic adenocarcinoma, distal pancreatic resection was performed in 127 (23.3%) of them, pancreaticoduodenal resection (PDR) – in 402 (73.8%), total pancreatectomy – in 16 (2.9%). Extended pancreatic resection was performed in 121 (22.2%) patients, including PDR – in 65 (53.7%), pancreatic distal resection – in 46 (38%), pancreatectomy – in 10 (8.3%).
Results. Complications have had occurred in 167 (39.4%) patients after standard pancreatic resection and in 51 (42.1%) – after the extended one (c2 = 0.29, p = 0.58). Lethality was 2.6% (14 patients died), of them 5 (4.1%) – after extended pancreatic resection, 9 (2.1%) – a standard one (c2 = 1.52, p = 0.22). Survival median and the general five–year survival indices are nontrustworthy lesser in patients after extended pancreatic resection than after a standard one – 21 mo and 26% and 28 mo and 29% (c2 = 0.15, p = 0.69), accordingly.
Conclusion. Lethality, morbidity rate, remote results after extended pancreatic resection are comparable with those after its standard resection.
References
2. Hartwig W, Gluth A, Hinz U, Koliogiannis D, Strobel O, Hackert T, et al. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer. Br J Surg. 2016 Nov;103(12):1683–94. DOI: 10.1002/bjs.10221.
3. Sinn M, Bahra M, Denecke T, Travis S, Pelzer U, Riess H. Perioperative treatment options in resectable pancreatic cancer – how to improve long–term survival. World J Gastrointest Oncol. 2016;8(3):248–57. DOI: 10.4251/wjgo.v8.i3.248.
4. Kasumova GG, Conway WC, Tseng JF. The role of venous and arterial resection in pancreatic cancer surgery. Ann Surg Oncol. 2016 Nov;23:1–8. DOI: 10.1245/s10434–016–5676–3.
5. Hartwig W, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, Adham M, et al. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery. 2014;156:1–14. DOI: 10.1016/i.surg.2014.02.009.
6. He J, Page AJ, Weiss M, Wolfgang CL, Herman JM, Pawlik TM. Management of borderline and locally advanced pancreatic cancer: where do we stand? World J Gastroenterol. 2014;20:2255–66. DOI: 10.3748/wjg.v20.i9.2255.
7. Selvaggi F, Mascetta G, Daskalaki D, Molin M, Salvia R., Butturini G.
Outcome of superior mesenteric–portal vein resection during pancreatectomy for borderline ductal adenocarcinoma: results of a prospective comparative study. Langenbeck’s Arch Surg. 2014;399:659–65. DOI:10.1007/s00423–014–1194–6.
8. Ohgi K, Yamamoto Y, Sugiura T, Okamura Y, Ito T, Ashida R. Is pancreatic head cancer with portal venous involvement really borderline resectable? Appraisal of an upfront surgery series. Ann Surg Oncol. 2017 Sep;24(9):2752–61. DOI:10.1245/s10434–017–5972–6.
9. Takaori K, Bassi C, Biankin A, Brunner T, Cataldo I, Campbell I, et al. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology. 2016;16:14–27. DOI:10.1016/j.pan.2015.10.013.
10. Ducreux M, Cuhna A, Caramella C, Hollebecque A, Burtin P, Goere D, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow–up. Ann Oncol. 2015;26, suppl 5: 56–68. DOI:10.1093/annonc/mdv295.